Berdagang Vir Biotechnology VIR

VirBiotechnology carta live

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

Berita Terkini

Frances Wang 2025 Apr 02, 16:00

USD/JPY Forecast: Analyzing Market Trends and Economic Indicators

Forex
Tommy Yap 2025 Apr 02, 16:00

Morning Note: U.S. Tariffs Shake Markets, Nikkei Sinks & Swiss Inflation Data Awaits

Morning Note USD
Frances Wang 2025 Apr 01, 16:00

Silver news today: Why has the silver price been volatile recently?

Commodities
three barrels of oil, neftechka, and American dollars against the background of a wooden table
Tommy Yap 2025 Mar 31, 21:00

Morning Note: US Jobs Data, Oil Steady on Tariffs, MicroStrategy BTC Bet

Oil Morning Note Cryptocurrencies
Frances Wang 2025 Mar 31, 16:00

Gold Prices Hit New Highs: What is Gold CFD trading?

Commodities
Frances Wang 2025 Mar 31, 16:00

Oil Markets Today: Oil Falls on OPEC+ Output Hike and Trump’s Tariffs

Commodities
Japan retail 
Tommy Yap 2025 Mar 29, 21:00

Morning Note: Japan Retail, China PMI, Germany Inflation

Japan Morning Note China
Tommy Yap 2025 Mar 29, 16:00

Week Ahead: U.S. Non-Farm Payrolls Coming Up: What to Expect

Forex Indices

Maklumat

Sebaran nilai

0.06

Spread (%)

1.0135 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran dibuka

Khamis

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

847543744

Saham Tertunggak

137143008

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-3.83

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Trustpilot